Literature DB >> 20863819

Bioactivation of antituberculosis thioamide and thiourea prodrugs by bacterial and mammalian flavin monooxygenases.

Clinton R Nishida1, Paul R Ortiz de Montellano.   

Abstract

The thioamide and thiourea class of antituberculosis agents encompasses prodrugs that are oxidatively converted to their active forms by the flavin monooxygenase EtaA of Mycobacterium tuberculosis. Reactive intermediates produced in the EtaA-catalyzed transformations of ethionamide and prothionamide result in NAD(+)/NADH adducts that inhibit the enoyl CoA reductase InhA, the ultimate target of these drugs. In the case of thiacetazone and isoxyl, EtaA produces electrophilic metabolites that mediate the antibacterial activity of these agents. The oxidation of the thioamide/thiourea drugs by the human flavin monooxygenases yields similar reactive metabolites that contribute to the toxicities associated with these second line antituberculosis drugs.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20863819      PMCID: PMC3033498          DOI: 10.1016/j.cbi.2010.09.015

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  24 in total

1.  Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria.

Authors:  Xavier Hanoulle; Jean-Michel Wieruszeski; Pierre Rousselot-Pailley; Isabelle Landrieu; Camille Locht; Guy Lippens; Alain R Baulard
Journal:  J Antimicrob Chemother       Date:  2006-08-08       Impact factor: 5.790

2.  Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid.

Authors:  Argyrides Argyrou; Matthew W Vetting; Bola Aladegbami; John S Blanchard
Journal:  Nat Struct Mol Biol       Date:  2006-04-30       Impact factor: 15.369

Review 3.  Treatment of active tuberculosis: challenges and prospects.

Authors:  Behzad Sahbazian; Stephen E Weis
Journal:  Clin Chest Med       Date:  2005-06       Impact factor: 2.878

Review 4.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

5.  Cross-resistance amongst thiambutosine, thiacetazone, ethionamide and prothionamide with Mycobacterium leprae.

Authors:  S R Pattyn; M J Colston
Journal:  Lepr Rev       Date:  1978-12       Impact factor: 0.537

6.  Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.

Authors:  D A Rozwarski; G A Grant; D H Barton; W R Jacobs; J C Sacchettini
Journal:  Science       Date:  1998-01-02       Impact factor: 47.728

7.  Monitoring of the ethionamide pro-drug activation in mycobacteria by (1)H high resolution magic angle spinning NMR.

Authors:  Xavier Hanoulle; Jean-Michel Wieruszeski; Pierre Rousselot-Pailley; Isabelle Landrieu; Alain R Baulard; Guy Lippens
Journal:  Biochem Biophys Res Commun       Date:  2005-06-03       Impact factor: 3.575

Review 8.  Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control.

Authors:  Surendra K Sharma; Alladi Mohan
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

9.  Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3.

Authors:  Lian Qian; Paul R Ortiz de Montellano
Journal:  Chem Res Toxicol       Date:  2006-03       Impact factor: 3.739

10.  The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.

Authors:  Y Zhang; B Heym; B Allen; D Young; S Cole
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

View more
  15 in total

1.  Mammalian flavin-containing monooxygenase (FMO) as a source of hydrogen peroxide.

Authors:  Lisbeth K Siddens; Sharon K Krueger; Marilyn C Henderson; David E Williams
Journal:  Biochem Pharmacol       Date:  2014-02-19       Impact factor: 5.858

2.  Heme and I.

Authors:  Paul R Ortiz de Montellano
Journal:  J Biol Chem       Date:  2015-07-20       Impact factor: 5.157

Review 3.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 4.  An overview on the proposed mechanisms of antithyroid drugs-induced liver injury.

Authors:  Reza Heidari; Hossein Niknahad; Akram Jamshidzadeh; Mohammad Ali Eghbal; Narges Abdoli
Journal:  Adv Pharm Bull       Date:  2015-03-05

5.  Baeyer-Villiger Monooxygenases EthA and MymA Are Required for Activation of Replicating and Non-replicating Mycobacterium tuberculosis Inhibitors.

Authors:  Sarah Schmidt Grant; Samantha Wellington; Tomohiko Kawate; Christopher A Desjardins; Melanie R Silvis; Carl Wivagg; Matthew Thompson; Katherine Gordon; Edward Kazyanskaya; Raymond Nietupski; Nathan Haseley; Noriaki Iwase; Ashlee M Earl; Michael Fitzgerald; Deborah T Hung
Journal:  Cell Chem Biol       Date:  2016-06-16       Impact factor: 8.116

6.  Potentiation of P2RX7 as a host-directed strategy for control of mycobacterial infection.

Authors:  Molly A Matty; Daphne R Knudsen; Eric M Walton; Rebecca W Beerman; Mark R Cronan; Charlie J Pyle; Rafael E Hernandez; David M Tobin
Journal:  Elife       Date:  2019-01-29       Impact factor: 8.140

Review 7.  The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

Authors:  Véronique Dartois
Journal:  Nat Rev Microbiol       Date:  2014-02-03       Impact factor: 60.633

8.  A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone.

Authors:  Anna E Grzegorzewicz; Jana Korduláková; Victoria Jones; Sarah E M Born; Juan M Belardinelli; Adrien Vaquié; Vijay A K B Gundi; Jan Madacki; Nawel Slama; Françoise Laval; Julien Vaubourgeix; Rebecca M Crew; Brigitte Gicquel; Mamadou Daffé; Hector R Morbidoni; Patrick J Brennan; Annaik Quémard; Michael R McNeil; Mary Jackson
Journal:  J Biol Chem       Date:  2012-09-21       Impact factor: 5.157

9.  Flavin-containing monooxygenase S-oxygenation of a series of thioureas and thiones.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Sharon K Krueger; J Fred Stevens; Karen Kedzie; Wenkui K Fang; Todd Heidelbaugh; Phong Nguyen; Ken Chow; Michael Garst; Daniel Gil; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2014-04-12       Impact factor: 4.219

10.  Xanthates: Metabolism by Flavoprotein-Containing Monooxygenases and Antimycobacterial Activity.

Authors:  Stanislav G Yanev; Tsveta D Stoyanova; Violeta V Valcheva; Paul R Ortiz de Montellano
Journal:  Drug Metab Dispos       Date:  2018-05-18       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.